An Update on Non-extremity Soft Tissue Sarcomas

S. J. Ford, L. M. Almond, A. Gronchi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The management of soft tissue sarcoma is challenging and varied. Centralisation of management in high volume specialist centres has revolutionised outcomes. Surgery remains the mainstay of treatment and is currently the only potentially curative therapy. Retroperitoneal soft tissue sarcoma presents a particular challenge to the surgical oncologist and the concept of extended resection to include surrounding expendable organs taken en bloc with the tumour has now largely been adopted. The use of neoadjuvant and adjuvant therapies for retroperitoneal soft tissue sarcoma is still to be established, although they are employed on a case-specific basis. Guidance on the management of retroperitoneal recurrences and distant metastatic disease is now recognised. The approach to soft tissue sarcoma of the head and neck, trunk and abdominal wall remains largely extrapolated from experience of the management of extremity soft tissue sarcoma. Secondary angiosarcoma of the breast is becoming increasingly more common and presents a particular therapeutic challenge. Continued international collaboration is essential to ensure evolution of the optimal management of this rare group of cancers.

Original languageEnglish
Pages (from-to)516-527
Number of pages12
JournalClinical Oncology
Volume29
Issue number8
DOIs
Publication statusPublished - Aug 1 2017

Fingerprint

Sarcoma
Neoadjuvant Therapy
Abdominal Wall
Neoplasms
Neck
Therapeutics
Extremities
Head
Recurrence

Keywords

  • Neoadjuvant and adjuvant therapies
  • retroperitoneal soft tissue sarcoma

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

An Update on Non-extremity Soft Tissue Sarcomas. / Ford, S. J.; Almond, L. M.; Gronchi, A.

In: Clinical Oncology, Vol. 29, No. 8, 01.08.2017, p. 516-527.

Research output: Contribution to journalArticle

Ford, S. J. ; Almond, L. M. ; Gronchi, A. / An Update on Non-extremity Soft Tissue Sarcomas. In: Clinical Oncology. 2017 ; Vol. 29, No. 8. pp. 516-527.
@article{50576203e2b9455798634f1f71970d5a,
title = "An Update on Non-extremity Soft Tissue Sarcomas",
abstract = "The management of soft tissue sarcoma is challenging and varied. Centralisation of management in high volume specialist centres has revolutionised outcomes. Surgery remains the mainstay of treatment and is currently the only potentially curative therapy. Retroperitoneal soft tissue sarcoma presents a particular challenge to the surgical oncologist and the concept of extended resection to include surrounding expendable organs taken en bloc with the tumour has now largely been adopted. The use of neoadjuvant and adjuvant therapies for retroperitoneal soft tissue sarcoma is still to be established, although they are employed on a case-specific basis. Guidance on the management of retroperitoneal recurrences and distant metastatic disease is now recognised. The approach to soft tissue sarcoma of the head and neck, trunk and abdominal wall remains largely extrapolated from experience of the management of extremity soft tissue sarcoma. Secondary angiosarcoma of the breast is becoming increasingly more common and presents a particular therapeutic challenge. Continued international collaboration is essential to ensure evolution of the optimal management of this rare group of cancers.",
keywords = "Neoadjuvant and adjuvant therapies, retroperitoneal soft tissue sarcoma",
author = "Ford, {S. J.} and Almond, {L. M.} and A. Gronchi",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.clon.2017.02.007",
language = "English",
volume = "29",
pages = "516--527",
journal = "Clinical Oncology",
issn = "0936-6555",
publisher = "W.B. Saunders Ltd",
number = "8",

}

TY - JOUR

T1 - An Update on Non-extremity Soft Tissue Sarcomas

AU - Ford, S. J.

AU - Almond, L. M.

AU - Gronchi, A.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - The management of soft tissue sarcoma is challenging and varied. Centralisation of management in high volume specialist centres has revolutionised outcomes. Surgery remains the mainstay of treatment and is currently the only potentially curative therapy. Retroperitoneal soft tissue sarcoma presents a particular challenge to the surgical oncologist and the concept of extended resection to include surrounding expendable organs taken en bloc with the tumour has now largely been adopted. The use of neoadjuvant and adjuvant therapies for retroperitoneal soft tissue sarcoma is still to be established, although they are employed on a case-specific basis. Guidance on the management of retroperitoneal recurrences and distant metastatic disease is now recognised. The approach to soft tissue sarcoma of the head and neck, trunk and abdominal wall remains largely extrapolated from experience of the management of extremity soft tissue sarcoma. Secondary angiosarcoma of the breast is becoming increasingly more common and presents a particular therapeutic challenge. Continued international collaboration is essential to ensure evolution of the optimal management of this rare group of cancers.

AB - The management of soft tissue sarcoma is challenging and varied. Centralisation of management in high volume specialist centres has revolutionised outcomes. Surgery remains the mainstay of treatment and is currently the only potentially curative therapy. Retroperitoneal soft tissue sarcoma presents a particular challenge to the surgical oncologist and the concept of extended resection to include surrounding expendable organs taken en bloc with the tumour has now largely been adopted. The use of neoadjuvant and adjuvant therapies for retroperitoneal soft tissue sarcoma is still to be established, although they are employed on a case-specific basis. Guidance on the management of retroperitoneal recurrences and distant metastatic disease is now recognised. The approach to soft tissue sarcoma of the head and neck, trunk and abdominal wall remains largely extrapolated from experience of the management of extremity soft tissue sarcoma. Secondary angiosarcoma of the breast is becoming increasingly more common and presents a particular therapeutic challenge. Continued international collaboration is essential to ensure evolution of the optimal management of this rare group of cancers.

KW - Neoadjuvant and adjuvant therapies

KW - retroperitoneal soft tissue sarcoma

UR - http://www.scopus.com/inward/record.url?scp=85015406736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015406736&partnerID=8YFLogxK

U2 - 10.1016/j.clon.2017.02.007

DO - 10.1016/j.clon.2017.02.007

M3 - Article

C2 - 28330704

AN - SCOPUS:85015406736

VL - 29

SP - 516

EP - 527

JO - Clinical Oncology

JF - Clinical Oncology

SN - 0936-6555

IS - 8

ER -